These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Abuse liability of mitragynine assessed with a self-administration procedure in rats. Yue K, Kopajtic TA, Katz JL. Psychopharmacology (Berl); 2018 Oct; 235(10):2823-2829. PubMed ID: 30039246 [Abstract] [Full Text] [Related]
5. Effects of alkaloid-rich extract from Mitragyna speciosa (Korth.) Havil. on naloxone-precipitated morphine withdrawal symptoms and local field potential in the nucleus accumbens of mice. Cheaha D, Reakkamnuan C, Nukitram J, Chittrakarn S, Phukpattaranont P, Keawpradub N, Kumarnsit E. J Ethnopharmacol; 2017 Aug 17; 208():129-137. PubMed ID: 28687506 [Abstract] [Full Text] [Related]
6. [Assessment of morphine-type physical dependence liability in mice using the drug-admixed food method]. Suzuki T, Yoshii T, Yanaura S. Nihon Yakurigaku Zasshi; 1984 Jul 17; 84(1):19-24. PubMed ID: 6541614 [Abstract] [Full Text] [Related]
8. Abuse liability and therapeutic potential of the Mitragyna speciosa (kratom) alkaloids mitragynine and 7-hydroxymitragynine. Hemby SE, McIntosh S, Leon F, Cutler SJ, McCurdy CR. Addict Biol; 2019 Sep 17; 24(5):874-885. PubMed ID: 29949228 [Abstract] [Full Text] [Related]
9. Effects of naloxone and D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 and the protein kinase inhibitors H7 and H8 on acute morphine dependence and antinociceptive tolerance in mice. Bilsky EJ, Bernstein RN, Wang Z, Sadée W, Porreca F. J Pharmacol Exp Ther; 1996 Apr 17; 277(1):484-90. PubMed ID: 8613958 [Abstract] [Full Text] [Related]
10. Phenylmethanesulfonyl fluoride, a serine protease inhibitor, suppresses naloxone-precipitated withdrawal jumping in morphine-dependent mice. Nemoto W, Sato T, Nakagawasai O, Yaoita F, Silberring J, Tadano T, Tan-No K. Neuropeptides; 2013 Jun 17; 47(3):187-91. PubMed ID: 23290539 [Abstract] [Full Text] [Related]
11. Nuclear factor-kappa-B inhibitor modulates the development of opioid dependence in a mouse model of naloxone-induced opioid withdrawal syndrome. Rehni AK, Bhateja P, Singh TG, Singh N. Behav Pharmacol; 2008 May 17; 19(3):265-9. PubMed ID: 18469544 [Abstract] [Full Text] [Related]
13. Blockade of endocannabinoid hydrolytic enzymes attenuates precipitated opioid withdrawal symptoms in mice. Ramesh D, Ross GR, Schlosburg JE, Owens RA, Abdullah RA, Kinsey SG, Long JZ, Nomura DK, Sim-Selley LJ, Cravatt BF, Akbarali HI, Lichtman AH. J Pharmacol Exp Ther; 2011 Oct 17; 339(1):173-85. PubMed ID: 21719468 [Abstract] [Full Text] [Related]
14. Acutely administered clozapine does not modify naloxone-induced withdrawal jumping in morphine-dependent mice. Ballard TM, McAllister KH. Pharmacol Biochem Behav; 1999 Feb 17; 62(2):285-90. PubMed ID: 9972695 [Abstract] [Full Text] [Related]
15. Activation of serotonin 5-HT(2C) receptor suppresses behavioral sensitization and naloxone-precipitated withdrawal symptoms in morphine-dependent mice. Zhang G, Wu X, Zhang YM, Liu H, Jiang Q, Pang G, Tao X, Dong L, Stackman RW. Neuropharmacology; 2016 Feb 17; 101():246-54. PubMed ID: 26432939 [Abstract] [Full Text] [Related]
16. Naloxone-precipitated withdrawal enhances ERK phosphorylation in prefrontal association cortex and accumbens nucleus of morphine-dependent mice. Li T, Hou Y, Cao W, Yan CX, Chen T, Li SB. Neurosci Lett; 2010 Jan 14; 468(3):348-52. PubMed ID: 19922770 [Abstract] [Full Text] [Related]
18. A survey of acute and chronic heroin dependence in ten inbred mouse strains: evidence of genetic correlation with morphine dependence. Klein G, Juni A, Waxman AR, Arout CA, Inturrisi CE, Kest B. Pharmacol Biochem Behav; 2008 Sep 14; 90(3):447-52. PubMed ID: 18472145 [Abstract] [Full Text] [Related]